0000950170-25-076525.txt : 20250522 0000950170-25-076525.hdr.sgml : 20250522 20250522183112 ACCESSION NUMBER: 0000950170-25-076525 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250520 FILED AS OF DATE: 20250522 DATE AS OF CHANGE: 20250522 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Savage William Jacob CENTRAL INDEX KEY: 0001951852 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39438 FILM NUMBER: 25978643 MAIL ADDRESS: STREET 1: C/O DISC MEDICINE, INC. STREET 2: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Disc Medicine, Inc. CENTRAL INDEX KEY: 0001816736 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 851613057 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (617) 674-9274 MAIL ADDRESS: STREET 1: 321 ARSENAL STREET, SUITE 101 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: Gemini Therapeutics, Inc. /DE DATE OF NAME CHANGE: 20210209 FORMER COMPANY: FORMER CONFORMED NAME: FS Development Corp. DATE OF NAME CHANGE: 20200702 4 1 ownership.xml 4 X0508 4 2025-05-20 0001816736 Disc Medicine, Inc. IRON 0001951852 Savage William Jacob C/O DISC MEDICINE, INC. 321 ARSENAL STREET, SUITE 101 WATERTOWN MA 02472 false true false false Chief Medical Officer true Common Stock 2025-05-20 4 S false 6677 50.0417 D 59721 D The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. By: /s/ Rahul Khara, as Attorney-in-Fact 2025-05-22